findmyKOL
Clinical trialNCT03686124RecruitingPhase 1/PHASE2Interventional

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

SponsorImmatics US, Inc.Enrollment375CancerRecurrent CancerRefractory CancerSolid Tumor, Adult
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Germany
  • Universitätsklinikum Heidelberg, Nationales Centrum Für Tumorerkrankungen (nct)

    Heidelberg, Baden-Wurttemberg, Germany

    Recruiting
  • Klinikum Rechts Der Isar Der Technischen Universität München

    Munich, Bavaria, Germany

    Recruiting
  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany

    Recruiting
  • Universitätsklinikum Bonn - Medizinische Klinik Iii

    Bonn, North Rhine-Westphalia, Germany

    Recruiting
  • Universitätsmedizin Der Johannes Gutenberg-Universität Mainz

    Mainz, Rhineland-Palatinate, Germany

    Recruiting
  • Universitätsklinikum C.-G.-Carus Dresden

    Dresden, Saxony, Germany

    Recruiting
  • Charité Benjamin Franklin - Klinik Für Hämatologie Und Onkologie

    Berlin, Germany

    Recruiting
  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

    Recruiting
United States
  • Stanford Cancer Institute

    Stanford, California, United States

    Recruiting
  • University of Colorado, Anschutz Medical Campus

    Aurora, Colorado, United States

    Recruiting
  • University of Miami Hospital and Clinics

    Miami, Florida, United States

    Recruiting
  • University of Chicago Medical Center

    Chicago, Illinois, United States

    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Recruiting
  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run

    Columbus, Ohio, United States

    Recruiting
  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, United States

    Anthony Olszanski, MD
    Recruiting
  • Thomas Jefferson University, Honickman Center

    Philadelphia, Pennsylvania, United States

    Recruiting
  • University of Pennsylvania, Perelamn Center for Advanced Medicine

    Philadelphia, Pennsylvania, United States

    Recruiting
  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, United States

    Jason Luke, M.D.
    Recruiting
  • University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

    Dejka M Araujo, M.D.
    Recruiting
  • Fred Hutchinson Cancer Center

    Seattle, Washington, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 May 2019
Primary completion
31 Dec 2028
Completion
30 Jun 2032
Last update posted
13 May 2026
Registered enrollment
375
Registry id
NCT03686124

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.